Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous ferric carboxymaltose vs oral iron in metastatic colorectal cancer with iron deficiency anemia
2014-000246-30Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ferric carboxymaltose in iron deficiency anemia (IDA) and colorectal cancer (CRC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Hemoglobin response. Started Jun 2014; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2014-000246-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000246-30.